NASDAQ$FOLD
Amicus Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Amicus Therapeutics reported strong Q1 2023 results with revenue growth and progress towards regulatory approvals and non-GAAP profitability.
Amicus Therapeutics announced a strong start to 2023, with Galafold driving revenue growth and progress made towards the approval and launch of AT-GAA. The company is on track to achieve non-GAAP profitability in the second half of the year.
- Q1 2023 revenue grew 14% at CER to $86.3 million.
- On track to deliver full-year 2023 Galafold revenue growth of 12%-17% at CER.
- U.S. FDA pre-approval inspection for AT-GAA complete; approval expected in Q3 2023.
- European launch of Pombiliti®+Opfolda® expected in Q3 2023.
Headline financials
Revenue & EPS history
Amicus Therapeutics · Revenue · Quarterly
$86.3M
Revenue by segment
Amicus Therapeutics · $100M total across 1 segment · Q3 2023
- Galafold$100M—100.0%
Forward guidance
Amicus Therapeutics is focused on growing Galafold, securing regulatory approvals and launching AT-GAA, and achieving non-GAAP profitability in the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.3%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+28.4%
Q3 2016
Best reaction
-16.1%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.2% | +0.0% | +0.6% | |
| Q3 2025 | +1.6% | +0.1% | +12.3% | |
| Q2 2025 | -2.5% | +14.0% | +23.8% | |
| Q1 2025 | -13.0% | -19.4% | -21.0% | |
| Q4 2024 | -2.9% | -5.2% | -8.5% | |
| Q3 2024 | -6.5% | -8.9% | -17.1% | |
| Q2 2024 | +14.8% | +17.2% | +16.5% | |
| Q1 2024 | -9.0% | -8.0% | -0.9% | |
| Q4 2023 | -7.4% | -2.8% | -14.9% | |
| Q3 2023 | -14.8% | -12.3% | -4.2% | |
| Q2 2023 | +9.1% | +7.0% | -1.4% | |
| Q1 2023 | -4.2% | -8.1% | +5.1% | |
| Q4 2022 | -3.9% | -8.1% | -15.9% | |
| Q3 2022 | +6.5% | +11.1% | +20.5% | |
| Q2 2022 | +17.5% | +19.2% | +10.5% | |
| Q1 2022 | +7.5% | +19.5% | +40.0% | |
| Q4 2021 | +0.0% | -0.5% | +13.2% | |
| Q3 2021 | -3.8% | -4.9% | -12.6% | |
| Q2 2021 | +8.5% | +7.6% | +20.1% | |
| Q1 2021 | -1.5% | -2.7% | +8.5% | |
| Q4 2020 | -9.0% | -14.7% | -19.5% | |
| Q3 2020 | -1.3% | +7.5% | +11.8% | |
| Q2 2020 | -5.3% | -6.6% | -9.5% | |
| Q1 2020 | -1.6% | +2.5% | +8.7% | |
| Q4 2019 | -4.2% | -0.6% | -7.2% | |
| Q3 2019 | +3.2% | +7.0% | +5.8% | |
| Q2 2019 | -8.5% | -12.0% | -21.9% | |
| Q1 2019 | -4.8% | -11.7% | -13.2% | |
| Q4 2018 | +12.0% | +9.1% | +9.4% | |
| Q3 2018 | -6.0% | -10.6% | -16.3% | |
| Q2 2018 | +4.7% | +5.4% | -16.8% | |
| Q1 2018 | -4.7% | -4.0% | +11.2% | |
| Q4 2017 | -6.2% | -9.0% | -0.7% | |
| Q3 2017 | -10.4% | -8.5% | -6.6% | |
| Q2 2017 | +1.1% | -8.9% | +6.3% | |
| Q1 2017 | +1.2% | +8.4% | +27.3% | |
| Q4 2016 | +14.5% | +18.5% | +9.9% | |
| Q3 2016 | +28.4% | +49.8% | -4.6% | |
| Q2 2016 | -9.5% | +0.0% | +1.4% | |
| Q1 2016 | -9.6% | — | — | |
| Q4 2015 | -4.3% | — | — | |
| Q3 2015 | +8.9% | — | — | |
| Q2 2015 | -16.1% | — | — | |
| Q1 2015 | -1.5% | — | — | |
| Q4 2014 | -0.5% | — | — | |
| Q3 2014 | -0.5% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | +0.5% | — | — | |
| Q4 2013 | +2.8% | — | — | |
| Q3 2013 | +3.9% | — | — | |
| Q2 2013 | +7.8% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q4 2012 | +11.0% | — | — | |
| Q3 2012 | -13.3% | — | — | |
| Q2 2012 | -5.5% | — | — | |
| Q1 2012 | +6.4% | — | — | |
| Q4 2011 | -4.9% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2011 | +6.7% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2010 | -4.4% | — | — | |
| Q3 2010 | -2.5% | — | — | |
| Q2 2010 | +10.0% | — | — | |
| Q1 2010 | -1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro